Testing atorvastatin for arrhythmogenic cardiomyopathy
Treatments studied
Part of Heart & circulation, Injuries & trauma clinical trials.
This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have arrhythmogenic cardiomyopathy, as diagnosed by your doctor using standard criteria.
- You cannot be taking any other cholesterol-lowering medications (like other statins, fibrates, or PCSK9 inhibitors).
- You must not have liver disease, muscle disease, or severe heart failure.
- You must not be pregnant, planning pregnancy, or breastfeeding; if you can become pregnant, you must use effective birth control.
- You must not have a known allergy to atorvastatin or any of its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called tideglusib to see if it can reduce extra heartbeats in people with a genetic form of arrhythmogenic cardiomyopathy. It may help stabilize the heart's rhythm and slow disease progression.
This study tests whether looking at your genes can help doctors understand and treat arrhythmic myocarditis (a type of heart muscle inflammation that can cause irregular heartbeats). It may help find better treatments for people with this condition.
This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.
This trial studies how well long-term cholesterol-lowering treatment works in people who recently had a heart attack (STEMI or NSTEMI). It may help your care team understand which patients benefit most and how treatment should be continued safely.
This trial tests whether two medicines, a statin and colchicine, can slow or stop early heart artery plaque from growing in people who have mild plaque but no heart disease symptoms yet. It uses special CT scans to measure plaque over 2 years.
This trial studies whether cholesterol-lowering medicine (a statin, specifically atorvastatin) improves health and benefits in people age 75 and older in everyday life. It may help doctors understand which older adults benefit most and how to use these medicines safely.
Hear when a new Arrhythmogenic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.